Basic Research and Discovery Stage Programs – Page 44

Using hiPSC-derived lung organoids, a clinically-relevant system, to validate & winnow a list of approved drugs that inhibit SARS-CoV-2 cytopathy

Post author:
Post published:September 12, 2024
Post category:

Research Objective Using authentic in vitro models of the human lung, complete with inflammatory cells & vessels, we will validate drugs that might be rapidly repurposed for use in patients…

Battling COVID-19 Using Off-The-Shelf HSC-Engineered iNKT Cells

Post author:
Post published:September 12, 2024
Post category:

Research Objective allogeneic HSC-engineered iNKT (HSC-iNKT) cells Impact treatment for COVID-19 Major Proposed Activities Milestone 1. Production of AlloHSC-iNKT and UHSC-iNKT cellsMilestone 2. Characterization of the AlloHSC-iNKT and UHSC-iNKT cellsMilestone…

Chimeric Antigen Receptor Targeting Spike Glycoprotein of SARS-cov2

Post author:
Post published:September 12, 2024
Post category:

Research Objective We expect to generate iPSC derived NK cells expressing a CAR against SARS-cov2 that could be used as an off-the-shelf therapy for COVID-19 Impact The proposed studies will…

Pro-healing biomaterial for treating lung inflammation associated with COVID-19

Post author:
Post published:September 12, 2024
Post category:

Research Objective Pro-healing biomaterial to treat lung inflammation and promote recovery. Impact COVID-19 associated acute respiratory distress syndrome Major Proposed Activities Evaluate biomaterial for ability to reduce lung inflammation in…

Persistent Off-the-Shelf meACE2-CAR-IL-15 NK Cells Derived from CD34(+) Cord Blood Stem Cells to Prevent and Treat COVID-19

Post author:
Post published:September 12, 2024
Post category:

Research Objective To develop and characterize meACE-2-CAR-IL15 NK cells expressing a mutated ACE2 and IL-15, allowing specific killing of SARS-CoV-2-infected cells and long in vivo persistence of the engineered cells.…

Identifying HLA Class I Restricted Peptides That Induce CD8+ T Cells Against SARS-CoV-2

Post author:
Post published:September 12, 2024
Post category:

Research Objective A vaccine to help prevent COVID-19 Impact There is a clear need for a vaccine to prevent the spread of the COVID-19 coronavirus that is effective, can be…

Application of PGE2/BPV, a muscle stem cell targeting therapeutic, to the treatment of COVID-19 associated diaphragm atrophy

Post author:
Post published:September 12, 2024
Post category:

Research Objective Intramuscular delivery of 2 repurposed FDA approved drugs to activate diaphragm stem cells to augment regeneration and restore strength to COVID-19 patients with diaphragm atrophy from ventilation. Impact…

Development of a novel PIKFYVE kinase inhibitor for the treatment of COVID-19

Post author:
Post published:September 12, 2024
Post category:

Research Objective Alveolar type II cells are the stem cells of the lung, and they are killed by SARS-CoV-2. We will determine if a novel PIKFYVE kinase inhibitor prevents SARS-CoV-2…

Biomaterial vaccine to enhance the formation of SARS-CoV-2-specific T memory stem cells

Post author:
Post published:September 12, 2024
Post category:

Research Objective The objective of this project is to develop an injectable biomaterial platform that can induce TMSCs and boost immunoactivation to vaccines against SARS-CoV-2, which will help protect elderly…

Stem cell-based rapid identification of SARS-CoV-2 T cell epitopes and T cell receptors for therapeutic use

Post author:
Post published:September 12, 2024
Post category:

Research Objective We will identify SAR-CoV-2 T cell epitopes for vaccine development and specific TCRs for adoptive T cell therapy using a stem cell-based platform to generate specialized dendritic cells…

Subscribe to Receive CIRM News